Immunological remission in PLA2R-antibody –associated membranous nephropathy: cyclophosphamide versus rituximab
For the treatment of patients with idiopathic membranous nephropathy, rituximab is considered an alternative to alkylating agents. Still, the nonresponse rate to rituximab is approximately 35%,1,2 and partial remission rate is lower with rituximab compared with cyclophosphamide.3 The discovery of antibodies against PLA2R (aPLA2R) has positioned immunological remission as a major goal in the treatment of idiopathic membranous nephropathy. We questioned whether rituximab is less effective than cyclophosphamide in inducing an immunological remission in patients with idiopathic membranous nephropathy.
Source: Kidney International - Category: Urology & Nephrology Authors: Anne-Els van de Logt, Karine Dahan, Alexandra Rousseau, Renate van der Molen, Hanna Debiec, Pierre Ronco, Jack Wetzels Tags: Letter to the Editor Source Type: research